Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants | ||
By: GlobeNewswire - 23 Nov 2020 | Back to overview list |
|
MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. 180 Life Sciences is an applicant and licensee of a broad and growing patent portfolio for three major drug platforms in the areas of inflammation, fibrosis and pain. The patent portfolio covers 16 patent families with 42 patents issued and 32 pending in several important jurisdictions, including the United States, Canada, Europe, Australia, Japan and China. On November 20, 2020, the Company received a notice from the USPTO that it will publish application 62/722,263 “Method of treating frozen shoulder using an il-33/TNF bispecific antibody”. The patent application is a continuation of US Patent No. 10,500,2730. Once the patent is granted, it will be assigned patent number US-2020-0338193-A 1. This is an additional part of a family of patents the Company has in its extensive patent portfolio. The Company also received a notice of acceptance for its US patent, “Method of treating early stage Dupuytren's Disease”, with the application number 16/089,234 filed September 27, 2018. Publication date is expected to occur on February 11, 2020. Additionally, the Company received notification that the EU has granted its application number 15726740.2, which was filed on August 29, 2016. The EU patent will be granted Dec 9, 2020, thereafter the Company chooses where in the EU it wishes to validate the patent. The Company has decided the following countries with the date of publication of the grant, no later than March 9, 2021: Austria, Belgium, Germany, Finland, France, Iceland, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, Liechtenstein, and United Kingdom. The Company’s patent portfolio consists of three main sets of IP, which correspond to the respective program. Anti-TNF Platform SCA Platform * one will be granted as noted above on Dec 9, 2020 ?7nAChR Other recent filings and grants include:
The Company’s patent portfolio is made up of both its own IP and exclusive worldwide licenses, with, Oxford University Innovation Limited, The Kennedy Trust for Rheumatology Research University of Oxford, Stanford University, and the Hebrew University. “The issuance of these additional patent assets significantly strengthens the IP portfolio governing our lead program,” said Dr. James Woody, CEO of 180 Life Sciences, “We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies. Having these most recent patents awarded, particularly in the EU, is important as it provides validation in the 12 largest countries in the EU, including the UK, and provides the platform to be able to expand clinical trials, commercialization and partnering efforts throughout Europe.” About 180 Life Sciences Corp. 180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. Forward-Looking Statements Investors: Jason Assad Media Relations: David Schull Eric Ando
|
||
|
||
Copyright 2020 GlobeNewswire | Back to overview list |